Join
Live feed
·
PRReleasevia Quantisnow
Serina Therapeutics Inc. logo

Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2

ByQuantisnow·Wall Street's wire, on your screen.
SER· Serina Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track SER (Serina Therapeutics Inc.) and more on Quantisnow.